Everything below concerns MC1R. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
=== Kniest dysplasia === Most mutations responsible for Kniest dysplasia result in abnormally short pro-alpha1(II) collagen chains that combine with normal-length chains, producing shorter-than-normal collagen molecules. This results in the characteristic features of Kniest dysplasia.
=== Appearance === Natural casing sausages are distinguishable from collagen or cellulose casings because of their irregularity, although high-quality sheep and lamb casings can be almost indistinguishable from a collagen casing as they have no noticeable imperfections. The main difference is in the way they are twisted and linked which affects the appearance of the final product and makes it easy to differentiate a hot dog using natural sheep or lamb casing vs collagen casing. The size and usage of natural casings relate to the animal from which they are derived, the narrowest being lamb followed by sheep followed by pig followed by beef. The size range for lamb is 14 mm to 28 mm in diameter (which is how casings are graded), the size range for sheep is 16 mm to 32 mm in diameter, the size range for pig is 28 mm to 58 mm in diameter, the size range for beef is 43 mm to 65 mm, although beef bung caps (which are not derived from the small intestine) have a size range of 115 mm to 130 mm.
=== Increase in age === When an individual ages, the outermost layer of skin becomes thin despite the number of cell layers remaining unchanged. The number of cells that contain pigment decreases, and the melanocytes that remain increase in size. This is why aging skin looks thin, pale, and translucent. Large spots may be pigmented when some areas are exposed to sunlight. The various alterations in the skin and underlying connective tissue may decrease its strength and elasticity. Also, the blood vessels in the outer skin become more delicate and can result in bruises and bleeding under the skin's surface. The subcutaneous glands also excrete decreased amounts of oil as you age. Men experience this shortage mostly after reaching the age of 80 years. Women may slowly begin excreting less oil after menopause, making it difficult to keep the skin moist. The subcutaneous fat layer also decreases, reducing the insulation and padding capability of the skin. This can put the individual at risk of an injury and makes maintaining body temperature difficult. The sweat glands also reduce the amount of sweat they produce, making the individual's body harder to cool.
Sources: en.wikipedia.org
=== Pretreatments === If the raw material used in the production of the gelatin is derived from bones, dilute acid solutions are used to remove calcium and other salts. Hot water or several solvents may be used to reduce the fat content, which should not exceed 1% before the main extraction step. If the raw material consists of hides and skin, then size reduction, washing, hair removal, and degreasing are necessary to prepare the materials for the hydrolysis step.
=== Stability and half-lives === Of isotopes whose half-lives are known, the lighter isotopes usually have shorter half-lives. The three lightest known isotopes have half-lives of <50 μs; the lightest reported isotope 252Rf has a half-life of <1 μs. 256Rf, 258Rf, 260Rf are more stable at ~10 ms; 255Rf, 257Rf, 259Rf, and 262Rf live between 1 and 5 seconds; 261Rf, 265Rf, and 263Rf are more stable, at ~1.1, 1.5, and 10 minutes respectively. The most stable known isotope, 267Rf, is one of the heaviest, and has a half-life of about 48 minutes. Rutherfordium isotopes with an odd neutron number tend to have longer half-lives than their even–even neighbors because the odd neutron hinders spontaneous fission. The lightest isotopes were synthesized by direct fusion between two lighter nuclei and as decay products. The heaviest isotope produced by direct fusion is 262Rf; heavier isotopes have only been observed as decay products of elements with larger atomic numbers. The heavy isotopes 266Rf and 268Rf have also been reported as electron capture daughters of the dubnium (266Db and 268Db), but have short half-lives to spontaneous fission. It seems likely that the same is true for 270Rf, a possible daughter of 270Db. These three isotopes remain unconfirmed. In 1999, American scientists at University of California, Berkeley, announced that they had succeeded in synthesizing three atoms of 293Og. These parent nuclei were reported to have successively emitted seven alpha particles to form 265Rf, but their claim was retracted in 2001.
==== Democratic reaction ==== The narrow passage of OBBBA led to internal backlash and division in the Democratic Party. Three elderly Democratic representatives (Raúl Grijalva of Arizona, age 77; Sylvester Turner of Texas, age 70; and Gerry Connolly of Virginia, age 75) died in the first five months of 2025. If any of the three had been alive when the vote was taken, the result of the vote could have been different. The vote "quickly reignited an intraparty debate about gerontocracy and aging politicians clinging to power".
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.